The Clinical Research Program at the Cardiovascular Institute allows our physicians to participate in national studies which provide current data to enhance treatment protocols for cardiovascular issues.

Of course, we could not participate without our patients who volunteer to be a part of a clinical trial or registry. Through our participation, select patients may have access to new technologies or medical therapies that are not yet widely available. However, many studies are simply observational and collect data on how patients respond to various therapies that are already the standard of care, to determine where improvements may be needed.  No matter what type of research, it is our patients’ participation that provides the necessary data to make advancements in cardiovascular treatment.

The selection criteria for each study are very specific.

Most patients will not be asked to participate in research.  Patients who are considered a good candidate for a certain study, and are approached about participating, are under no obligation to enroll.  Your cardiologist and our research coordinator will provide you with comprehensive information to make an informed decision on your study participation and treatment options.  Patients who participate in studies are monitored, most commonly through follow-up appointments, for a prescribed amount of time per the study requirements.  Patients are asked to please consider their long term commitment to attend all follow-up appointments as part of their participation.  While patients can certainly choose to remove themselves from a study, it is our hope that those who choose to enroll will work with us to complete their participation.

At Cardiovascular Institute, we believe that our participation in clinical research gives us access to new data and information that continually improves the quality of care we provide to all of our patients.  We’re proud to bring this level of commitment to treating cardiovascular disease to our community.

If  you have any questions regarding your eligibility for studies that Cardiovascular Institute is currently participating in you may contact our research coordinator:

Shelley Sherk at (850)769-0329

Links to trials actively enrolling at Cardiovascular Institute of Northwest Florida


The purpose of this trial is to test the effectiveness of an innovative, clinic-level educational intervention to improve the management of patients with Type II Diabetes and Cardiovascular Disease.

Principal Investigator:  Michael Morrow, M.D.



In addition, to view a short video explanation of the objectives of this trial and to learn who may be a candidate visit

Principal Investigator:  Amir Haghighat, M.D.


The objective of C2R is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial ( ID NCT02089217). Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with carotid artery stenting (CAS) performed by experienced and skilled interventionists. Interventionists’ eligibility will be determined by a multi-specialty Interventional Management Committee (IMC). Patient eligibility will include patients with standard or high-risk, symptomatic or asymptomatic carotid artery disease. Patients will be followed for the occurrence of post-procedural complications. The primary safety and quality endpoint will be the occurrence of any stroke or death within the 30-day period following the stenting procedure.

Principal Investigator:  Amir Haghighat, M.D.


Patients who receive a Medtronic device may qualify for this registry. Please see the patient brochure for more information.  Click here to view brochure.

Principal Investigator:  Nghia Hoang, D.O.


The main goal of this study is to use data from the Bodyport scale to help detect worsening heart failure (HF).  See Video.

Principal Investigator:  Amir Haghighat, M.D.

Links to trials Cardiovascular Institute continues to monitor

Pioneer III

The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary stents.

Principal Investigator:  Amir Haghighat, M.D.


The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

Principal Investigator: Nghia Hoang, D.O